NCT01862029View on ClinicalTrials.gov

Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 22, 2013

Primary Completion Date

July 25, 2017

Study Completion Date

July 25, 2017

Conditions
Obesity
Interventions
DRUG

Roflumilast

Selective phosphodiesterase 4 (PDE4) inhibitor

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT01862029 - Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals | Biotech Hunter | Biotech Hunter